Renaissance Technologies (RenTech)'s TVTX Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 1.97 M shares of Travere Therapeutics, Inc. (TVTX) worth $58.43 M, representing 0.09% of the portfolio. First purchased in 2020-Q4, this long-term strategic position has been held for 22 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in TVTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2023, adding 1.09 M shares. Largest reduction occurred in Q3 2025, reducing 743,000 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Travere Therapeutics (TVTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Travere Therapeutics (TVTX) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -280,000 | Reduce 12.46% | 1.97 M | $29.71 |
| Q4 2025 | +494,665 | Add 28.23% | 2.25 M | $38.21 |
| Q3 2025 | -743,000 | Reduce 29.78% | 1.75 M | $23.90 |
| Q2 2025 | -207,700 | Reduce 7.68% | 2.5 M | $14.80 |
| Q1 2025 | +293,300 | Add 12.17% | 2.7 M | $17.92 |
| Q4 2024 | +534,500 | Add 28.51% | 2.41 M | $17.42 |
| Q3 2024 | -328,800 | Reduce 14.92% | 1.88 M | $13.99 |
| Q2 2024 | -658,200 | Reduce 23.00% | 2.2 M | $8.22 |
| Q1 2024 | -219,000 | Reduce 7.11% | 2.86 M | $7.71 |
| Q4 2023 | +1.09 M | Add 54.50% | 3.08 M | $8.99 |
| Q3 2023 | +439,109 | Add 28.24% | 1.99 M | $8.94 |
| Q2 2023 | -589,809 | Reduce 27.50% | 1.56 M | $0.02 |
| Q1 2023 | +551,300 | Add 34.60% | 2.14 M | $0.02 |
| Q4 2022 | +86,100 | Add 5.71% | 1.59 M | $0.02 |
| Q3 2022 | -149,600 | Reduce 9.03% | 1.51 M | $24.64 |
| Q2 2022 | +299,700 | Add 22.08% | 1.66 M | $24.23 |
| Q1 2022 | +317,400 | Add 30.52% | 1.36 M | $25.77 |
| Q4 2021 | -200,496 | Reduce 16.16% | 1.04 M | $31.04 |
| Q3 2021 | -470,904 | Reduce 27.52% | 1.24 M | $24.25 |
| Q2 2021 | +122,600 | Add 7.72% | 1.71 M | $14.59 |
| Q1 2021 | -272,700 | Reduce 14.65% | 1.59 M | $24.97 |
| Q4 2020 | +1.86 M | New Buy | 1.86 M | $27.25 |
Renaissance Technologies (RenTech)'s Travere Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Travere Therapeutics, Inc. (TVTX) in Q4 2020, acquiring 1,861,422 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Travere Therapeutics, Inc. (TVTX) for 22 quarters since Q4 2020.
Renaissance Technologies (RenTech)'s largest addition to Travere Therapeutics, Inc. (TVTX) was in Q4 2020, adding 1,861,422 shares worth $50.73 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 1,966,779 shares of Travere Therapeutics, Inc. (TVTX), valued at approximately $58.43 M.
As of the Q1 2026 filing, Travere Therapeutics, Inc. (TVTX) represents approximately 0.09% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Travere Therapeutics, Inc. (TVTX) was 3,081,014 shares, as reported at the end of Q4 2023.